74975OsteoMiR -- a novel disease-modifying drug for the treatment of osteoarthritis.ClosedStudyUKRI Inn.ScholarOsteoarthritis (OA) is the leading cause of disability in older adults with 1 in 8 being affected. Around 75% of people with OA report constant pain, with approximately 30% giving up work or reducing the number of hours they work due to the condition. The cost of OA in the USA and Europe has been estimated at 1-2.5% of GDP. Currently, there are no Disease-Modifying OA Drugs (DMOAD). Loss of cartilage is believed to be a major cause of osteoarthritis symptoms and therefore, therapies that limit or reverse this damage are likely to reduce symptoms and benefit patients. Causeway Therapeutics is developing a treatment that uniquely targets the cellular pathways that drive the development of OA stopping disease progression, restoring function and reducing pain.